AAAAAA
Results:
1-11
|
Results: 11
Authors:
NIELSEN H
PAPPOT H
CHRISTENSEN IJ
BRUNNER N
THORLACIUSUSSING O
MOESGAARD F
DANO K
GRONDAHLHANSEN J
Citation: H. Nielsen et al., ASSOCIATION BETWEEN PLASMA-CONCENTRATIONS OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND SURVIVAL IN PATIENTS WITH COLORECTAL-CANCER, BMJ. British medical journal, 316(7134), 1998, pp. 829-830
Authors:
GRONDAHLHANSEN J
CHRISTENSEN IJ
BRIAND P
PAPPOT H
MOURIDSEN HT
BLICHERTTOFT M
DANO K
BRUNNER N
Citation: J. Grondahlhansen et al., PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IN CYTOSOLIC TUMOR EXTRACTS PREDICTS PROGNOSIS IN LOW-RISK BREAST-CANCER PATIENTS, Clinical cancer research, 3(2), 1997, pp. 233-239
Authors:
PAPPOT H
PFEIFFER P
GRONDAHLHANSEN J
SKOV BG
Citation: H. Pappot et al., PRESENCE OF UROKINASE PLASMINOGEN-ACTIVATOR, ITS INHIBITOR AND RECEPTOR IN SMALL-CELL LUNG-CANCER AND NONSMALL CELL LUNG-CANCER, International journal of oncology, 10(1), 1997, pp. 177-182
Authors:
PAPPOT H
HOYERHANSEN G
RONNE E
HANSEN HH
BRUNNER N
DANO K
GRONDAHLHANSEN J
Citation: H. Pappot et al., ELEVATED PLASMA-LEVELS OF UROKINASE PLASMINOGEN-ACTIVATOR RECEPTOR INNONSMALL CELL LUNG-CANCER PATIENTS, European journal of cancer, 33(6), 1997, pp. 867-872
Authors:
PAPPOT H
SKOV BG
PYKE C
GRONDAHLHANSEN J
Citation: H. Pappot et al., LEVELS OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 AND UROKINASE PLASMINOGEN-ACTIVATOR RECEPTOR IN NONSMALL CELL LUNG-CANCER AS MEASURED BY QUANTITATIVE ELISA AND SEMIQUANTITATIVE IMMUNOHISTOCHEMISTRY, Lung cancer, 17(2-3), 1997, pp. 197-209
Authors:
DEWITTE H
PAPPOT H
BRUNNER N
GRONDAHLHANSEN J
HOYERHANSEN G
BEHRENDT N
GULDHAMMERSKOV B
SWEEP F
BENRAAD T
DANO K
Citation: H. Dewitte et al., ELISA FOR COMPLEXES BETWEEN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND ITS RECEPTOR IN LUNG-CANCER TISSUE-EXTRACTS, International journal of cancer, 72(3), 1997, pp. 416-423
Authors:
PAPPOT H
FRANCIS D
BRUNNER N
GRONDAHLHANSEN J
OSTERLIND K
Citation: H. Pappot et al., P53 PROTEIN IN NON-SMALL-CELL LUNG-CANCER AS QUANTITATED BY ENZYME-LINKED-IMMUNOSORBENT-ASSAY - RELATION TO PROGNOSIS, Clinical cancer research, 2(1), 1996, pp. 155-160
Authors:
GRONDAHLHANSEN J
PETERS HA
VANPUTTEN WLJ
LOOK MP
PAPPOT H
RONNE E
DANO K
KLIJN JGM
BRUNNER N
FOEKENS JA
Citation: J. Grondahlhansen et al., PROGNOSTIC-SIGNIFICANCE OF THE RECEPTOR FOR UROKINASE PLASMINOGEN-ACTIVATOR IN BREAST-CANCER, Clinical cancer research, 1(10), 1995, pp. 1079-1087
Authors:
PAPPOT H
GARDSVOLL H
ROMER J
PEDERSEN AN
GRONDAHLHANSEN J
PYKE C
BRUNNER N
Citation: H. Pappot et al., PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IN CANCER - THERAPEUTIC AND PROGNOSTIC IMPLICATIONS, Biological chemistry Hoppe-Seyler, 376(5), 1995, pp. 259-267
Authors:
PAPPOT H
BRUNNER N
Citation: H. Pappot et N. Brunner, PLASMINOGEN ACTIVATION SYSTEM AND ITS ROLE IN LUNG-CANCER - A REVIEW, Lung cancer, 12(1-2), 1995, pp. 1-12
Authors:
RONNE E
PAPPOT H
GRONDAHLHANSEN J
HOYERHANSEN G
PLESNER T
HANSEN NE
DANO K
Citation: E. Ronne et al., THE RECEPTOR FOR UROKINASE PLASMINOGEN-ACTIVATOR IS PRESENT IN PLASMAFROM HEALTHY DONORS AND ELEVATED IN PATIENTS WITH PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA, British Journal of Haematology, 89(3), 1995, pp. 576-581
Risultati:
1-11
|